TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05560321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sani24
Description: Disinfectant

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Disinfection
Description: Routine disinfection at the study hospital
Study: NCT03478124

Intervention type: BEHAVIORAL
Intervention: Cognitive evaluation
Description: An extensive battery of neuropsychological and motor tests was assessed: MMSE, FAB, MoCA, WCST, Stroop Test, TMT-A and B, Verbal fluency Test, ROCF copy and delayed recall, RAVLT, 6MWT, TUG, BBS.

Intervention type: BEHAVIORAL
Intervention: Cognitive evaluation
Description: An extensive battery of neuropsychological and motor tests was assessed: MMSE, FAB, MoCA, WCST, Stroop Test, TMT-A and B, Verbal fluency Test, ROCF copy and delayed recall, RAVLT, 6MWT, TUG, BBS.
Study: NCT01703312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: Drug administered by subcutaneous injection
Study: NCT05560321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Disinfection
Description: Routine disinfection at the study hospital
Study: NCT01492803

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Probiotic is a live microorganism that when administered in adequate amounts confer a health benefit on the host. It is classified by the FDA as generally recognized as safe (GRAS)
Study: NCT01703312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omalizumab
Description: Drug administered by subcutaneous injection
Study: NCT01492803

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo sticks will contain approximately 1 g maltodextrin
Study: NCT03446573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG + 3TC
Description: DTG+3TC is supplied as white, oval, film-coated, fixed dose combination tablet. The tablets will be available in packed high density polyethylene (HDPE) bottles with induction seals and child-resistant closures.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAF based regimen (TBR)
Description: Participants will continue to receive their TBR.
Study: NCT04641039

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior lumbar disc annulus removal versus replacement
Description: Owestry scale, SF12, Facet joint arthritis measured with Pathria scale, discal degeneration measured with Modic and Phirrmann scales

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior lumbar disc annulus removal versus replacement
Description: Owestry scale, SF12, Facet joint arthritis measured with Pathria scale, discal degeneration measured with Modic and Phirrmann scales
Study: NCT04031768

Intervention type: OTHER
Group type: OTHER
Intervention: Timing of rest prior to blood pressure measurement
Description: Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which they rest prior to each set of measurements.

Intervention type: OTHER
Group type: OTHER
Intervention: Timing of rest prior to blood pressure measurement
Description: Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which they rest prior to each set of measurements.

Intervention type: OTHER
Group type: OTHER
Intervention: Timing of rest prior to blood pressure measurement
Description: Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which they rest prior to each set of measurements.

Intervention type: OTHER
Group type: OTHER
Intervention: Timing of rest prior to blood pressure measurement
Description: Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which they rest prior to each set of measurements.

Intervention type: OTHER
Group type: OTHER
Intervention: Timing of rest prior to blood pressure measurement
Description: Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which they rest prior to each set of measurements.

Intervention type: OTHER
Group type: OTHER
Intervention: Timing of rest prior to blood pressure measurement
Description: Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which they rest prior to each set of measurements.
Study: NCT04900857

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry needle
Description: Local twitch responses (LTRs) were obtained by multiple rapid insertions of the needle in and out of the point, similar to Hong's rapid-entry and rapid exit technique. Hong 1994). The needle was not removed from that site for the maximum stimulation time of 1 minute to 3 minutes after a local twitch response was obtained.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Localize vibration
Description: the vibration was applied with 110 Hz and 5.57 mm amplitude.
Study: NCT04275635

Intervention type: DEVICE
Intervention: Orthokeratology lenses
Description: Orthokeratology lenses
Study: NCT03286075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS Anode session
Description: The aim of this unique anode tDCS session is to study the possibility of enhancing emotional processing, attentional resources and physiological responses in healthy subjects.~The arm will be compared to the other 2, enabling us to compare different tDCS stimulation modes.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system).
Study: NCT02055547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 35μg
Description: Single dose 35μg subcutaneous (SC) injection in a treatment period (Part 3, Panel H)
Study: NCT03286075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS Cathode session
Description: The aim of this unique cathode tDCS session is to study the possibility of inhibiting or altering emotional processing, attentional resources and physiological responses in healthy subjects.~This arm will be compared to the other 2, enabling us to compare different tDCS stimulation modes.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Cathode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and anode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS Placebo session
Description: This arm will help compare the effects of stimulation versus no stimulation on emotional processing, attentional resources and physiological responses.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)
Study: NCT01951456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health and Wellness
Study: NCT00315029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: evidence based decision aid
Description: evidence based decision aid

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Possible reimbursement 4th IVF/ICSI cycle when necessary
Description: Potential reimbursement 4th IVF/ICSI cycle when necessary
Study: NCT03096990

Intervention type: DRUG
Intervention: apremilast
Description: Psoriatic arthritis patients treated with Otezla® (apremilast) in Belgium
Study: NCT04548050

Intervention type: OTHER
Intervention: Nurses training
Description: * Presentation of the benefits of colostrum and manual expression technique on a slide show and practical workshops for learning the manual expression technique on a fictitious breast.~* Presentation to all staff of a service protocol for early colostrum donation.

Intervention type: OTHER
Intervention: Nurses training
Description: * Presentation of the benefits of colostrum and manual expression technique on a slide show and practical workshops for learning the manual expression technique on a fictitious breast.~* Presentation to all staff of a service protocol for early colostrum donation.
Study: NCT01703312

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Drug administered by subcutaneous injection
Study: NCT00787735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling compliance
Description: Rates of attendance to call counseling session over specific time points

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling compliance
Description: Rates of attendance to call counseling session over specific time points
Study: NCT03514225

Intervention type: OTHER
Group type: OTHER
Intervention: Metacognitive Therapy for Social Anxiety
Description: The transdiagnostic Metacognitive model posits that psychological disorder stems from the activation of a perseverative thinking style called the CAS (Cognitive Attentional Syndrome). This has 3 key elements: worry/rumination, threat-focussed attention and unhelpful coping behaviours. Each of these elements results in extended cognitive responses to negative thoughts, prolonging negative emotions and maintaining an individual's sense of threat. The CAS arises from an individual's positive and negative metacognitive beliefs (beliefs about cognition). Metacognitive Therapy (MCT) aims to bring the CAS under control by modifying metacognitive beliefs and enabling individuals to develop new reactions to negative thoughts.
Study: NCT02407015

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nintendo 3DS gameplay
Study: NCT01805115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Description: Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Description: Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
Study: NCT01805115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Description: Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control
Description: The control group was not given any cervical priming agents or placebo.
Study: NCT02639559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplant
Study: NCT00772967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen tablets 500 mg twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Twice daily on Day 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen tablets 500 mg twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Twice daily on Day 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen tablets 500 mg twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Twice daily on Day 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen tablets 500 mg twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Twice daily on Day 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen tablets 500 mg twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Twice daily on Day 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen tablets 500 mg twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Twice daily on Day 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
Study: NCT02170012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06743649
Description: 20 mg tablet once daily dosing for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet once daily dosing for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06743649
Description: To be decided dose, tablet once daily dosing for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet once daily dosing for 14 days
Study: NCT02170012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06743649
Description: To be decided dose, tablet once daily dosing for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet once daily dosing for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06743649
Description: To be decided dose, tablet once daily dosing for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet once daily dosing for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06743649
Description: To be decided dose, tablet once daily dosing for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet once daily dosing for 14 days
Study: NCT04539899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR+
Description: Use of a virtual reality helmet during IUD insertion
Study: NCT02609633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek® CONNECT DMS
Description: SMBG will be performed during the 6-month study using the Accu-Chek® Aviva CONNECT monitoring device, and corresponding Smartphone app and online tracking tool.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DMS
Description: SMBG will be performed during the 6-month study according to usual care, using the participant's current DMS (other than Accu-Chek® CONNECT DMS).
Study: NCT00200083

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcend II Model 8848
Description: All subjects will be implanted with the IGS device and then randomized to on or off for 12 months. After 12 months all subjects will be turned on through 24 month follow up.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcend II Model 8848
Description: All subjects will be implanted with the IGS device and then randomized to on or off for 12 months. After 12 months all subjects will be turned on through 24 month follow up.
Study: NCT02256774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study: NCT00772967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
Study: NCT03203512

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil capsules
Description: Each serving contains 360mg eicosapentaenoic acid (EPA), 270mg docosahexaenoic acid (DHA) and total supplement is 1.8 g per day n-3 PUFA for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High-oleic safflower oil capsules
Description: High-oleic safflower oil capsules for 12 weeks
Study: NCT01189890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: Sitagliptin tablets, orally, at a dose of 100 mg or 50 mg QD for 30 weeks. The dose level to be administered will depend on the participant's estimated glomerular filtration rate (eGFR), calculated at Visit 3 and may be adjusted as medically indicated during the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride tablets, orally, starting at a dose of 1 mg QD, which may be gradually increased, as needed, to maximum dose of 6 mg QD for 30 weeks. The dose may also be decreased as medically indicated during the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Sitagliptin
Description: Matching placebo tablets to sitagliptin to allow for blinding.
Study: NCT00858052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saline-filled breast implant [IDEAL IMPLANT (R)]
Description: Breast augmentation
Study: NCT01604031

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B-CLL Vaccine
Description: Patients will receive a fixed dose (2X10\^7) of IL-2 secreting B-cells together with (2X10\^7) of hCD40L expressing B-cells. Patients will receive doses of vaccine at 2 week intervals for 5 doses. Barring adverse events, an additional 11 doses of vaccine will be given, at 4 weekly intervals beginning on week 12 for a total period of one year or 16 vaccinations in total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Subjects will begin lenalidomide 5 mg orally daily on day zero and will continue daily dosing until week 60 (4 weeks after the final dose of vaccine).
Study: NCT04614779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN128 Tablets
Description: Iron chelator, oral tablets
Study: NCT02917499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Transcranial magnetic stimulation
Study: NCT00741949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Sedation in TCI with propofol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isotonic saline solution infusion
Study: NCT02993302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1α-D3
Description: patients were given PTU and 1α-D3
Study: NCT03733145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Participants in the ACE inhibitors, ARBs, and Other Classes of Antihypertensive Agents who's systolic blood pressure (SBP) is less than 80% of the baseline reading is detected, will have Ang II initiated at 2 ng/kg/min through a peripheral IV. The infusion will be increased at the discretion of the clinical team based on the response of the patient until a SBP within 5% of the baseline SBP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Participants in the ACE inhibitors, ARBs, and Other Classes of Antihypertensive Agents who's systolic blood pressure (SBP) is less than 80% of the baseline reading is detected, will have Ang II initiated at 2 ng/kg/min through a peripheral IV. The infusion will be increased at the discretion of the clinical team based on the response of the patient until a SBP within 5% of the baseline SBP.